<DOC>
	<DOCNO>NCT02427035</DOCNO>
	<brief_summary>This phase 1 multicenter , randomize , double-blind , placebo-controlled , ascend dose study investigate pharmacokinetics ( PK ) , safety , tolerability CSL112 adult subject moderate renal impairment healthy adult subject normal renal function .</brief_summary>
	<brief_title>A Study CSL112 Healthy Adults Adults With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Men woman age 18 85 year ( inclusive ) age , body weight 50 kg . Subjects renal impairment ( RI ) must stable chronic moderate RI ( estimate glomerular filtration rate [ eGFR ] ≥ 30 &lt; 60 mL/min/1.73 m2 ) Healthy subject must normal renal function ( eGFR ≥ 90 mL/min/1.73 m2 ) Evidence clinically significant medical condition , disorder disease Evidence hepatobiliary disease Any clinically relevant abnormal laboratory test result Known history allergy , hypersensitivity deficiency CSL112 components Other severe comorbid condition , concurrent medication , issue render subject unsuitable participation study , include : history cancer , low platelet count , bleed disorder coagulopathy , significantly alter electrocardiogram waveform , unstable glycemia control subject diabetes , acute renal failure , recent donation loss blood Evidence history alcohol substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>